Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis
PLOS ONE · 02.01.2025 · 20 (1) · e0315512
DOI: 10.1371/journal.pone.0315512 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 02.01.2025. Verfasst von Qin Zhou und 6 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Shen…. Hauptthemen laut MEDLINE: Fluoroquinolones, Isoniazid, Mycobacterium smegmatis, Rifampin. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shenzhen Science and Technology Program, Shenzhen High-level Hospital Construction Fund, Shenzhen Clinical Research Center for Tuberculosis.
Abstract (Originalsprache)
Background
The emergence of drug-resistant Tuberculosis (TB) has made treatment challenging. Although fluoroquinolones (FQs) are used as key drugs in the treatment of multidrug-resistant tuberculosis (MDR-TB), the problem of FQs resistance is becoming increasingly serious. Rifampicin (RIF) resistance is considered a risk factor for FQs resistance. The objective of this study was to investigate the impact of RIF and isoniazid (INH) resistance on the FQs resistance in vitro experiment.
Methods
FQs resistant strains were selected in vitro from RIF and/or INH resistant Mycobacterium smegmatis ( M . sm ). The sequencing of the gyrA gene, and the minimum inhibitory concentration (MIC) of FQs (ciprofloxacin, levofloxacin, moxifloxacin and gatifloxacin) were performed for FQs-resistant strains.
Results
A total of 222 FQs-resistant M . sm strains were selected, all of which had the gyrA mutation. Seven gyrA mutations were detected, with mutations at loci 90 and 94 being the most common. There were no differences in FQs resistance developed from RIF and/or INH resistant M . sm . There was a significant difference in the MIC of the gyrA mutant types to FQs. The highest resistance to FQs was observed in the Gly88Cys mutant strains. M . sm with the identical gyrA mutation showed the highest resistance to ciprofloxacin and relatively low resistance to gatifloxacin and moxifloxacin.
Conclusions
In this study, we found no evidence that RIF and/or INH resistance directly affects FQs resistance in M . sm in vitro experiments. Resistance profiles of different gryA mutations to the four FQs drugs were also presented. These findings provide a more comprehensive understanding of FQs resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Clinical Research Center for Infectious Diseases, Shenzhen Clinical Research Center for Tuberculosis, Shenzhen Third People's Hospital, Shenzhen, Guangdong, China.
- Zunyi Medical University, Zunyi, Guizhou, China.
ORCID-Profile: Peng Xu
Förderung
- Shenzhen Science and Technology Program
- Shenzhen High-level Hospital Construction Fund
- Shenzhen Clinical Research Center for Tuberculosis
- National College Students' innovation and entrepreneurship training program
- Students' innovation and entrepreneurship training program of Guizhou Province
Zitieren
APA
Zhou, Q., Pu, N., Xu, G., Liu, H., Jia, X., Wang, X., & Xu, P. (2025). Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis. PLOS ONE, 20(1), e0315512. https://doi.org/10.1371/journal.pone.0315512
Vancouver
Zhou Q, Pu N, Xu G, Liu H, Jia X, Wang X, et al. Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis. PLOS ONE. 2025;20(1):e0315512. doi:10.1371/journal.pone.0315512
BibTeX
@article{Zhou2025,
author = {Zhou, Qin and Pu, Na and Xu, Ge and Liu, Hangchi and Jia, Xudong and Wang, Xiaomin and Xu, Peng},
title = {Rifampicin and isoniazid resistance not promote fluoroquinolone resistance in Mycobacterium smegmatis},
journal = {PLOS ONE},
year = {2025},
volume = {20},
number = {1},
pages = {e0315512},
doi = {10.1371/journal.pone.0315512}
}
EUVIMED